Antisense oligonucleotide inhibition of cholesteryl ester transfer protein enhances RCT in hyperlipidemic, CETP...

Area of Science:

• Biochemistry
• Pharmacology
• Cardiovascular Medicine

Background:

• Cholesteryl ester transfer protein (CETP) plays a role in lipoprotein metabolism.
• CETP inhibitors are being developed as therapeutics for cardiovascular disease.
• Understanding the comparative efficacy of different CETP inhibition strategies is crucial.

Purpose of the Study:

• To compare the efficacy of a CETP antisense oligonucleotide (ASO) inhibitor with a small molecule inhibitor, anacetrapib.
• To evaluate the effects on lipid profiles, CETP activity, and reverse cholesterol transport.
• To assess the impact on aortic cholesterol accumulation in a mouse model.

Main Methods:

• Utilized hyperlipidemic CETP transgenic (tg) mice.
• Administered a CETP ASO inhibitor and anacetrapib.
• Measured plasma lipids, CETP activity, HDL cholesterol, and macrophage reverse cholesterol transport.
• Analyzed CETP mRNA levels and aortic cholesterol content.

Main Results:

• Both CETP ASO and anacetrapib reduced total plasma cholesterol and CETP activity, and increased HDL cholesterol.
• CETP ASO treatment uniquely enhanced macrophage reverse cholesterol transport and reduced plasma triglycerides.
• ASO-mediated CETP mRNA reduction correlated with decreased aortic cholesterol accumulation.

Conclusions:

• CETP ASOs represent a potential alternative therapeutic strategy for cardiovascular disease.
• ASO-mediated CETP inhibition may offer advantages over small molecule inhibitors in specific aspects of cholesterol metabolism.
• Further development of CETP ASOs for human cardiovascular disease treatment is warranted.